NCT00499720Approved For Marketing不适用
Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:
- •≥ 6 years of age
- •Subject has CF as diagnosed by one of the following:
- •Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test
- •Two well characterized genetic mutations in the CFTR gene
- •Abnormal nasal potential difference with accompanying symptoms characteristic of CF
- •At high risk for disease progression as defined by one of the following subject populations:
- •First Cohort Criteria:
- •Those who are wait listed or eligible for lung transplant based on FEV1 criteria. Patients who have a level of lung function impairment consistent with lung transplantation criteria, but who are ineligible for transplantation for other reasons, can enroll in this program; or
- •Completed participation in CP-AI-006 (through Visit 20). Subjects who withdraw from CP-AI-006 prior to completing all courses of AZLI and all study visits will not be eligible for this protocol.
- •Second Cohort Criteria:
- •Meets first cohort criteria
- •FEV1 ≤ 40% predicted at the time of consent
- •Third Cohort Criteria:
- •Meets first or second cohort criteria
- •FEV1 ≤ 50% predicted at the time of consent
排除标准
- •Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
- •Subjects with any serious or active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance with the protocol or dosing requirements
- •Subjects with hypersensitivity to any of the components of the drug product
- •Currently enrolled in another clinical trial
- •Pregnant or lactating females
研究者
相似试验
Approved For Marketing
不适用
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic FibrosisPseudomonas AeruginosaCystic FibrosisNCT00989807Gilead Sciences
进行中（未招募）
不适用
Program to Give the Drug Aztreonam Lysine for Inhalation to Patients with Cystic Fibrosis and infection by the Bacteria Pseudomonas aeruginosa Who Have Limited Treatment Options and are at Risk for Disease ProgressioAdult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.EUCTR2015-000396-26-Outside-EU/EEAGilead Sciences, Inc.603
进行中（未招募）
不适用
Program to Give the Drug Aztreonamn Lysine for Inhalation to Canadian Patients with Cystic Fibrosis and infection by the Bacteria Pseudomonas aeruginosa Who Have Limited Treatment Options and are at Risk for Disease ProgressioEUCTR2015-000397-36-Outside-EU/EEAGilead Sciences, Inc.45
No Longer Available
不适用
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.
No Longer Available
不适用
18F-Floretyrosine Expanded Access ProgramGlioma (Any Grade) in the BrainNCT06743100Telix Pharmaceuticals (Innovations) Pty Limited